Evidence map›Paper›PMID 36858772›Full record

ArticleAdvances in pharmacology (San Diego, Calif.)2023

Arsenic and cancer: Evidence and mechanisms.

Rachel M Speer, Xixi Zhou, Lindsay B Volk, Ke Jian Liu, Laurie G Hudson

Open access · greenAbstract read
In one paragraph

Article in Advances in pharmacology (San Diego, Calif.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
52.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Lung Cancer Screening and Prevention: Beyond Conventional Strategies in a Rapidly Changing Global Milieu.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rachel M SpeerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, United States.
Xixi ZhouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, United States.
Lindsay B VolkDepartment of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, United States.
Ke Jian LiuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, United States; Stony Brook Cancer Center, Renaissance School of Medicine, State University of New York Stony Brook, Stony Brook, NY, United States. Electronic address: kliu@salud.unm.edu.
Laurie G HudsonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, United States.
University of New Mexico · US

Funding

University of New Mexico Center for Metals in Biology and Medicine - equipment supplementP20GM130422 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Sebastian Medina · 2020 to 2026
$20.4M
UNM Metals Exposure and Toxicity Assessment on tribal Lands in the Southwest (METALS) Superfund Research ProgramP42ES025589 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BOLT, ALICIA M. · 2017 to 2025
$16.4M
Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet RadiationR01ES030993 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HUDSON, LAURIE G, LIU, KE JIAN · 2020 to 2024
$2.5M
The Role of Biotransformation in Arsenic-Induced HematotoxicityR01ES029369 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LIU, KE JIAN · 2018 to 2022
$1.8M
NIEHS NIH HHS P42 ES025589NIEHS NIH HHS R01 ES029369NIEHS NIH HHS R01 ES030993NIGMS NIH HHS P20 GM130422
6 · The paper itself

Abstract

Arsenic is a potent carcinogen and poses a significant health concern worldwide. Exposure occurs through ingestion of drinking water and contaminated foods and through inhalation due to pollution. Epidemiological evidence shows arsenic induces cancers of the skin, lung, liver, and bladder among other tissues. While studies in animal and cell culture models support arsenic as a carcinogen, the mechanisms of arsenic carcinogenesis are not fully understood. Arsenic carcinogenesis is a complex process due its ability to be metabolized and because of the many cellular pathways it targets in the cell. Arsenic metabolism and the multiple forms of arsenic play distinct roles in its toxicity and contribute differently to carcinogenic endpoints, and thus must be considered. Arsenic generates reactive oxygen species increasing oxidative stress and damaging DNA and other macromolecules. Concurrently, arsenic inhibits DNA repair, modifies epigenetic regulation of gene expression, and targets protein function due its ability to replace zinc in select proteins. While these mechanisms contribute to arsenic carcinogenesis, there remain significant gaps in understanding the complex nature of arsenic cancers. In the future improving models available for arsenic cancer research and the use of arsenic induced human tumors will bridge some of these gaps in understanding arsenic driven cancers.

Indexed as

ArsenicNeoplasmsAnimalsCarcinogenesisCarcinogensEpigenesis, GeneticHumansArsenicCarcinogensArsenicCancerCarcinogenesisDNA damageMechanism

Identifiers

PMID36858772
PMCPMC10860672
OpenAlexW4312815570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.